2008 |
RA, SHH, BDNF, GDNF, CTNF |
30 |
20 |
Dimos et al. (2008)
|
2009 |
RA, SHH, BDNF, GDNF, IGF-1 |
35 |
>40 |
Hu & Zhang, (2009)
|
2009 |
RA, PMA, GDNF, BDNF, CTNF |
48–62 |
>35 |
Karumbayaram et al. (2009)
|
2012 |
SB, Dorsomorphin, RA, PMA, BDNF, GDNF, forskolin |
71 |
>10 |
Bilican et al. (2012)
|
2013 |
LDN, SB, RA, SHH, BDNF, GDNF, CNTF |
31 |
30 |
Amoroso et al. (2013)
|
2013 |
RA, PMA, GDNF, BDNF |
31 |
40 |
Sareen et al. (2013)
|
2014 |
LDN, SB, RA, SAG, PMA, BDNF, GDNF, CNTF |
31 |
>30 |
Grunseich et al. (2014)
|
2013 |
Dorsomorphin, RA, SHH, BDNF, GDNF, IGF-1 |
20 |
70 |
Qu et al. (2014)
|
2015 |
Dorsomorphin, SB, BIO (GSK inhibitor), RA, PMA, c-AMP, BDNF, GDNF, IGF-1 |
28–42 |
>60 |
Shimojo et al. (2015)
|
2015 |
SB, LDN, RA, SAG, CHIR, DAPT |
25 |
70 |
Maury et al. (2015)
|
2015 |
CHIR, DMH-1, SB, RA, PMA, BDNF, GDNF, CNTF, IGF-1, Compound E |
30 |
95 |
Du et al. (2015)
|
2016 |
RA, SHH, c-AMP, BDNF, GDNF, IGF-1 |
21–30 |
40 |
Dafinca et al. (2016)
|
2016 |
LDN, SB, RA, PMA, CHIR, c-AMP, BDNF, GDNF, IGF-1 |
28 |
80 |
Hu et al. (2016)
|
2018 |
CHIR, DMH-1, SB, RA, PMA, BDNF, GDNF, CNTF, IGF-1, Compound E |
18–53 |
60 |
Sances et al. (2018)
|
2018 |
CHIR, Dorsomorphin, Compound E, SHH, SAG, PMA, RA, CTNF, BDNF, GNDF, NT-3 |
21 |
73 |
Bianchi et al. (2018)
|
2018 |
SB, CHIR, Dosormorphin, RA, PMA, DAPT, db-cAMP, BDNF, GDNF, IGF-1 |
40 |
70 |
Fujimori et al. (2018)
|
2018 |
LDN, SB, RA, SHH, BDNF, GDNF, CNTF |
27 |
20 |
Bossolasco et al. (2018)
|
2019 |
SB, Dorsomorphin, RA, PMA, BDNF, GDNF, forskolin |
28–42 |
>90 |
Bax et al. (2019)
|
2020 |
CHIR, DMH-1, SB, RA, PMA, BDNF, GDNF, CNTF, IGF-1, Compound E |
28 |
67 |
Thiry et al. (2020)
|
2020 |
Dorsomorphin, FGF2, Noggin, SB, RA, SHH, BDNF, GDNF, IGF-1 |
20 |
80 |
Faye et al. (2020)
|
2020 |
SB, LDN, RA, SAG, CHIR, DAPT |
29 |
>90 |
Garcia-Diaz et al. (2020)
|
2021 |
LDN, SB, IWR1e, CHIR, RA, PMA, DAPT |
28–42 |
16 |
Sato et al. (2021)
|
2021 |
RA, PMA, BDNF, GDNF, IGF-1, c-AMP |
28–52 |
>90 |
Cutarelli et al. (2021)
|